MAP2K7 and melanoma: This shortcoming of PI3K/AKT/mTOR inhibitors as therapeutic targets in melanoma treatment is attributed to feedback loops derived from the inhibition of PI3K/mTOR leading to the activation/reactivation of aberrant signaling pathways like RAS/RAF/MEK/ERK [39,40].